Dechra Pharmaceuticals has signed an agreement with Piedmont Pharmaceuticals LLC which gives Dechra exclusive worldwide rights to the sale and distribution of veterinary products which use Piedmont's proprietary soft chew platform to deliver the active ingredient.
The agreement will allow Dechra to conduct studies necessary to achieve regulatory filings and government approvals within the US, Europe and other key countries.
According to Dechra, Piedmont's soft chew formulation is a unique delivery technology which overcomes the traditional problems in formulating a broad range of active drug compounds in a highly palatable chewy treat for both cats and dogs.
Ian Page, CEO of Dechra Pharmaceuticals PLC, said: "We are very excited about licensing this unique delivery technology, which will be the first soft chew product with this new patent pending technology in the veterinary market. The agreement will provide Dechra with the opportunity to expand our presence in the companion animal market with a truly differentiated product."Roland Johnson, Chairman and CEO of Piedmont Pharmaceuticals, said: "This is our initial development partnership for our soft chew technology and we welcome the opportunity to license our technology to Dechra. Our goal is to provide pet owners the added benefit of a tasty treat at medicine time, creating a fun and rewarding interaction, while improving compliance with the vet prescribed treatment regimen."